CN1151788C - 卡维地洛-盖仑制剂 - Google Patents

卡维地洛-盖仑制剂 Download PDF

Info

Publication number
CN1151788C
CN1151788C CNB998046876A CN99804687A CN1151788C CN 1151788 C CN1151788 C CN 1151788C CN B998046876 A CNB998046876 A CN B998046876A CN 99804687 A CN99804687 A CN 99804687A CN 1151788 C CN1151788 C CN 1151788C
Authority
CN
China
Prior art keywords
active substance
water
pharmaceutical preparation
minutes
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998046876A
Other languages
English (en)
Chinese (zh)
Other versions
CN1295472A (zh
Inventor
R－D
R-D·加贝尔
W·普雷斯
A·沃尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998116036 external-priority patent/DE19816036A1/de
Priority claimed from EP98112241A external-priority patent/EP0968714A1/de
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of CN1295472A publication Critical patent/CN1295472A/zh
Application granted granted Critical
Publication of CN1151788C publication Critical patent/CN1151788C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNB998046876A 1998-04-09 1999-04-01 卡维地洛-盖仑制剂 Expired - Fee Related CN1151788C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE1998116036 DE19816036A1 (de) 1998-04-09 1998-04-09 Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
DE19816036.4 1998-04-09
EP98112241.9 1998-07-02
EP98112241A EP0968714A1 (de) 1998-07-02 1998-07-02 Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen

Publications (2)

Publication Number Publication Date
CN1295472A CN1295472A (zh) 2001-05-16
CN1151788C true CN1151788C (zh) 2004-06-02

Family

ID=26045401

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998046876A Expired - Fee Related CN1151788C (zh) 1998-04-09 1999-04-01 卡维地洛-盖仑制剂

Country Status (12)

Country Link
EP (1) EP1069896B1 (da)
JP (2) JP3947654B2 (da)
KR (1) KR100520589B1 (da)
CN (1) CN1151788C (da)
AR (1) AR018179A1 (da)
AT (1) ATE246502T1 (da)
AU (1) AU3522399A (da)
CA (1) CA2326840C (da)
DE (1) DE69910188T2 (da)
DK (1) DK1069896T3 (da)
ES (1) ES2204121T3 (da)
WO (1) WO1999052526A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
BR0312102A (pt) 2002-06-27 2007-05-29 Sb Pharmco Inc sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento
CA2492084A1 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
JP2007512372A (ja) 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
JP5072364B2 (ja) 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
EP2259801B1 (en) 2008-03-04 2012-01-04 Lupin Limited Stable pharmaceutical compositions of carvedilol
TWI415604B (zh) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
JP5602936B2 (ja) * 2010-03-29 2014-10-08 フイルメニツヒ ソシエテ アノニム 噴霧乾燥した結晶性活性成分
CN104528744A (zh) * 2015-01-15 2015-04-22 中国药科大学 一种扩孔介孔二氧化硅的简单制备及其促溶应用
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH0249720A (ja) * 1988-05-18 1990-02-20 Mitsubishi Kasei Corp 難溶性薬剤組成物
JPH0776516A (ja) * 1993-09-06 1995-03-20 Toyobo Co Ltd 難溶性薬物含有製剤の製造方法
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets

Also Published As

Publication number Publication date
CA2326840A1 (en) 1999-10-21
JP3947654B2 (ja) 2007-07-25
EP1069896A1 (en) 2001-01-24
DE69910188T2 (de) 2004-06-17
AR018179A1 (es) 2001-10-31
DE69910188D1 (de) 2003-09-11
KR100520589B1 (ko) 2005-10-10
KR20010042574A (ko) 2001-05-25
JP2007145856A (ja) 2007-06-14
AU3522399A (en) 1999-11-01
DK1069896T3 (da) 2003-11-17
WO1999052526A1 (en) 1999-10-21
CA2326840C (en) 2007-08-07
CN1295472A (zh) 2001-05-16
JP2002511413A (ja) 2002-04-16
EP1069896B1 (en) 2003-08-06
ATE246502T1 (de) 2003-08-15
ES2204121T3 (es) 2004-04-16

Similar Documents

Publication Publication Date Title
US8349366B2 (en) Immediate release pharmaceutical granule compositions and a continuous process for making them
TWI389691B (zh) 可口服且具有活性成分快速釋出之固態醫藥劑型
JP2011063611A (ja) シロスタゾール製剤
CN100560067C (zh) 盐酸决奈达隆口服药物组合物及其制备方法
JP2007145856A (ja) カルベジロール製剤
JP4748839B2 (ja) シロスタゾール製剤
WO2008128028A2 (en) Solifenacin compositions
JP3624954B1 (ja) 分散不良薬物の溶出性を改善する方法
CN1237104A (zh) 可迅速崩解的小药丸
JP2006528221A5 (da)
KR20150123838A (ko) 안정한 글루코키나제 활성화제 조성물
US6852337B2 (en) Carvedilol-galenics
CA2253769C (en) Pharmaceutical compositions comprising fenofibrate
WO2005020979A1 (en) A process for the preparation of pharmaceutical compositions of nateglinide
JP2025037671A (ja) ダパグリフロジンプロピレングリコール水和物の凝集性の改善方法およびダパグリフロジンプロピレングリコール水和物含有医薬の製造方法
CN1228019A (zh) 含有水溶性化合物和纤维素的颗粒
JPH05139973A (ja) ニフエジピン含有固形製剤の製造方法
JP6072705B2 (ja) 固体分散体製剤
US20160000732A1 (en) Oral pharmaceutical compositions of ospemifene
WO2025261499A1 (zh) 蛋白激酶Mek抑制剂苯并噻唑的颗粒药物组合物
CN119454591A (zh) 一种哒嗪类衍生物的纳米晶颗粒、组合物及其制备方法
JP4438941B2 (ja) 分散不良薬物の溶出性を改善する方法
CN121550163A (zh) 一种阿利沙坦酯口服固体制剂及其制备方法
WO2017209216A1 (ja) 難溶性薬物の微粒子を含有する医薬組成物の製造方法
WO2004103361A2 (en) A pharmaceutical dosage form of citalopram

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040602